Company news
Spruce Biosciences, Inc. news in 2025
Spruce Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
December 14, 2025
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 10, 2025
Spruce Biosciences Announces $50.0 Million Private Placement Financing
October 7, 2025
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
October 5, 2025
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
September 15, 2025
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B
August 15, 2025
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 13, 2025
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
August 13, 2025
Spruce Biosciences Announces Reverse Stock Split
July 23, 2025
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
July 22, 2025
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
June 11, 2025
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 6, 2025
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
April 14, 2025
Decks in 2025
- Corporate Update (April 2025)
Corporate update · 15 slides · Apr 15, 2025